Payment overview · 2025
General Payments
$781.37
41 reported records · 16 companies
Healthcare provider profile · identity verified
Kimberly A Snyder, APRN BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · RICHMOND, IN · NPI 1265416341
Verified facts
What the public records show
CMS Open Payments records show Kimberly A Snyder, APRN BC received $781.37 in general payments during 2025 across 41 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $150.11 | 19.2% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $109.31 | 14.0% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $90.13 | 11.5% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $80.71 | 10.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $69.39 | 8.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.55 | 5.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $38.27 | 4.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.19 | 4.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.65 | 4.7% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $31.67 | 4.0% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $21.34 | 2.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.03 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.11 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.66 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.15 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.10 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $731.42 | 40 |
| Long term medical supply or device loan | $49.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $150.11 | 10 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $109.31 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $90.13 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $80.71 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $49.95 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $38.27 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.65 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $31.67 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 140 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
140 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
130 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 567 | 125 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 536 | 84 |
| Gabapentin | Gabapentin | 459 | 73 |
| Omeprazole | Omeprazole | 437 | 90 |
| Alprazolam | Alprazolam | 392 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 336 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 72 |
| Lisinopril | Lisinopril | 323 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 282 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 244 | 53 |
| Trazodone Hcl | Trazodone Hcl | 227 | 41 |
| Potassium Chloride | Potassium Chloride | 218 | 38 |
| Famotidine | Famotidine | 205 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 28 |
| Furosemide | Furosemide | 164 | 41 |
| Pregabalin | Pregabalin | 161 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 150 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 149 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 146 | 33 |
| Montelukast Sodium | Montelukast Sodium | 144 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 143 | 28 |
| Prednisone | Prednisone | 143 | 28 |
| Ozempic | Semaglutide | 140 | 22 |
| Losartan Potassium | Losartan Potassium | 138 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 29 |
| Eliquis | Apixaban | 130 | 28 |
| Metformin Hcl | Metformin Hcl | 127 | 26 |
| Tramadol Hcl | Tramadol Hcl | 127 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 26 |
| Sertraline Hcl | Sertraline Hcl | 122 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 121 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 36 |
| Meloxicam | Meloxicam | 108 | 21 |
| Buspirone Hcl | Buspirone Hcl | 106 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 104 | 24 |
| Aripiprazole | Aripiprazole | 103 | 13 |
| Baclofen | Baclofen | 99 | 20 |
| Lorazepam | Lorazepam | 95 | 18 |
| Simvastatin | Simvastatin | 94 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 20 |
| Clonazepam | Clonazepam | 82 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 75 | 14 |
| Nystatin | Nystatin | 74 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 19 |
| Diazepam | Diazepam | 69 | suppressed |
| Ibuprofen | Ibuprofen | 69 | 14 |
| Allopurinol | Allopurinol | 68 | 16 |
| Spironolactone | Spironolactone | 68 | 15 |
| Mounjaro | Tirzepatide | 66 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 12 |
| Linzess | Linaclotide | 62 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 61 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 60 | suppressed |
| Ondansetron Odt | Ondansetron | 60 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 15 |
| Atenolol | Atenolol | 53 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 50 | suppressed |
| Carvedilol | Carvedilol | 49 | 12 |
| Clonidine Hcl | Clonidine Hcl | 47 | suppressed |
| Methylprednisolone | Methylprednisolone | 47 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 33 |
| Fluconazole | Fluconazole | 46 | 23 |
| Mirtazapine | Mirtazapine | 46 | 11 |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 11 |
| Memantine Hcl Er | Memantine Hcl | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 13 |
| Ezetimibe | Ezetimibe | 41 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Mupirocin | Mupirocin | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 23 |
| Loperamide | Loperamide Hcl | 35 | 19 |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 14 |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Leflunomide | Leflunomide | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 17 |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 14 |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 15 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $781.37 · 41 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AUSTEDO XR, Auvelity, CAPLYTA, EVENITY, FREESTYLE INSULINX, FREESTYLE LIBRE 3, INGREZZA, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, Ozempic, PROLIA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, Tymlos, VOQUEZNA, Veozah, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error